Adjuvant and induction chemotherapy in non-small cell lung cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Pirker, Robert ^a,b   Malayeri, R ^a   Huber, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant chemotherapy; Induction chemotherapy; Induction therapy; Multimodality treatment; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 0033386914     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S71     Document Type: Conference Paper

References (38)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
3. Pirker R, Krajnik G, Zochbauer S et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 1995; 6: 833-5.
4. Le-Chevalier T, Brisgand D, Douillard JY et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1996; 12:360-7.
5. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303.
6. nd, Langer M et al. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 1996; 77: 2393-9.
7. Holmes EC. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. Chest 1994; 106: 293S-296S.
8. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 1993; 85: 299-306.
9. Niiranen A, Niitamo-Korhonen S, Kouri M et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomised study. J Clin Oncol. 1992; 12: 1927-32.
10. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996; 14: 1048-54.
11. Ohta M, Tsuchiya R, Shimoyama M et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomised prospective study. Thorac Cardiovasc Surg 1993; 106: 703-8.
12. Ferguson MK, Little AG, Golomb HM et al. The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer. J Thorac Cardiovasc Surg 1986; 91: 344-9.
13. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metu-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
14. Feld R. Chemotherapy as adjuvant therapy for completely resected non-small-cell lung cancer: have we made progress? J Clin Oncol 1996; 14: 1045-7.
15. Fontanini G, Lucchi M, Vignati S et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6.
16. Pastorino U, Andreola S, Tagliabue E et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.
17. Fontanini G, Vignati S. Lucchi M et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75: 1295-301.
18. Krajnik G, Huber H, Pirker R. Cellular drug resistance in lung cancer. Onkologie 1997; 20:310-4.
19. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198: 386-97.
20. Sugarbaker DJ, Herndon J, Kohman LJ et al. Results of cancer and leukemia group B protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995; 109: 473-85.
21. Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: a meta analysis of the literature. Lung Cancer 1991; 7: 243-5.
22. Burkes RL, Ginsberg RJ, Shepherd FA et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol 1992; 10: 580-6.
23. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-73.
24. Pujol JL, Hayot M, Rouanet P et al. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer. Chest 1994; 106: 1451-5.
25. Elias AD, Skarin AT, Leong T et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997; 17: 147-61.
26. Skarin A, Jochelson M, Sheldon T et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40: 266-74.
27. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83: 266-73.
28. Strauss GM, Herndon JE, Sherman DD et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10: 1237-44.
29. Deutsch M, Crawford J, Leopold K et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer 1994; 74: 1243-52.
30. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-92.
31. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16: 622-34.
32. Choi NC, Carey RW, Daly W et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15: 712-22.
33. Roth JA, Fossella F, Komaki R et al. A randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
34. Rosell R, Gomez Codina J, Camps C et al. A randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 1994; 330: 153-8.
35. Pass HI, Pogrebniak HW, Steinberg SM et al. Randomised trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53: 992-8.
36. Cullen MH. Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. Oncology 1993; 50(Suppl 1): 31-4.
37. Splinter TAW, Kirkpatrick A, Darwish S, van Meerbeeck J. Randomised trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction chemotherapy. Intergroup Study 08941. Lung Cancer 1997; 18 (Suppl 1):62-3 (abstract 239).
38. Pisters KMW, Ginsberg RJ. Phase II trial of induction paclitaxel & carboplatin in early stage (T2N0, T1-2N1 & selected T3N0-1) non-small cell lung cancer. Proc ASCO 1998; 17: 454 (abstract 1738).